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The cannabinoid CB2 receptor is known to modulate
osteoclast function by poorly understood mecha-
nisms. Here, we report that the natural biphenyl neoli-
gnan 40-O-methylhonokiol (MH) is a CB2 receptor-
selective antiosteoclastogenic lead structure (Ki <
50 nM). Intriguingly, MH triggers a simultaneous Gi
inverse agonist response and a strong CB2 receptor-
dependent increase in intracellular calcium. The
most active inverse agonists from a library of MH
derivatives inhibited osteoclastogenesis in RANK
ligand-stimulatedRAW264.7 cells andprimary human
macrophages. Moreover, these ligands potently in-
hibited the osteoclastogenic action of endocannabi-
noids. Our data show that CB2 receptor-mediated
cAMP formation, but not intracellular calcium, is
crucially involved in the regulation of osteoclastogen-
esis, primarily by inhibiting macrophage chemotaxis
and TNF-a expression. MH is an easily accessible
CB2 receptor-selective scaffold that exhibits a novel
type of functional heterogeneity.
INTRODUCTION
The cannabinoid type 2 (CB2) receptor is a G protein-coupled
receptor (GPCR) widely expressed in different tissues, including
bone (Atwood and Mackie, 2010; Bab and Zimmer, 2008).
Modulation of CB2 receptor activity has been shown to be
involved in the pathophysiology of different diseases, including
osteoporosis, atherosclerosis, chronic pain, cancer, and distinct
inflammatory conditions (Di Marzo, 2009; Buckley, 2008). The
CB2 receptor is part of the endocannabinoid system (ECS),
which comprises the formation, transport, and degradation of
the endogenous ligands arachidonoyl ethanolamide (ananda-
mide; AEA) and 2-arachidonoyl glycerol (2-AG) (Muccioli,
2010). AEA and 2-AG nonselectively bind to both CB1 and CB2Chemistry & Biology 18, 1053–receptors with Ki values in the lower nanomolar range (Hanus
and Mechoulam, 2010). The action of endocannabinoids at the
CB2 receptor typically starts the regulation of cAMP formation
(via Gi proteins) (Bosier et al., 2010). This GPCR is negatively
coupled via Gi/o to adenylyl cyclase (AC), and CB2 inverse
agonists (including SR144528) stimulate forskolin-activated AC
activity (Rinaldi-Carmona et al., 1998). 2-AG has been shown
to be a full agonist of the CB2 receptor as it induces a maximal
inhibitory Gi response leading to full cAMP inhibition and also
leads to significant [Ca2+]i transients in peripheral cells including
myeloid cells (Sugiura et al., 2000). The CB2 receptor-mediated
release of intracellular calcium in myeloid cells has been sug-
gested to potentially play a role in immune cell function (Chicca
et al., 2009; Gokoh et al., 2007; Sugiura et al., 2000). Indepen-
dent studies with CB2 receptor agonists have reported a CB2
receptor-mediated induction of [Ca2+]i release in different cells,
as well as the modulation of different mitogen-activated protein
(MAP) kinases (Shoemaker et al., 2005a; Malysz et al., 2009).
However, not all CB2 receptor agonists trigger a [Ca
2+]i release
and not all CB2 receptor-selective antagonists (inverse agonists)
are able to block these [Ca2+]i transients (Shoemaker et al.,
2005b; Sugiura et al., 2000). Thus, the mechanism of CB2
receptor-mediated induction of [Ca2+]i and its potential func-
tional effects in primary cells remains poorly understood. More-
over, [Ca2+]i triggered via CB2 receptors has only played a
marginal role in the classification of CB2 receptor ligands. Typi-
cally, CB2 receptor agonists, neutral antagonists, inverse ago-
nists and protean agonists are generally described based on
their Gi coupled effects (Bosier et al., 2010).
The CB2 receptor has been independently shown by different
groups to regulate osteoclastogenesis and bone resorption and
to play a role in bone homeostasis (Karsak et al., 2005; Idris et al.,
2005, 2008; Ofek et al., 2006). In addition to expression in oste-
oclasts, the CB2 receptor is also expressed in osteoblasts where
it was recently shown to stimulate bone formation via a Gi-cyclin
D1 mechanism (Ofek et al., 2011). The ECS is most strongly ex-
pressed in monocytes/macrophages, which are the precursor
cells of osteoclasts (Nakashima and Takayanagi, 2009; Matias
et al., 2002). Thus, macrophage differentiation into osteoclasts
may be critically modulated by the function of the ECS through1064, August 26, 2011 ª2011 Elsevier Ltd All rights reserved 1053
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Novel Biphenyl-Type CB2 Receptor Inverse Agonistsactivation of CB receptors. Upon stimulation of monocytes/
macrophages by receptor activator of NF-kB ligand (RANKL),
the transcription factor NF-ATc is activated and the mono-
cytes/macrophages start to fuse and differentiate to form multi-
nucleated cells (syncytia), the preosteoclasts. Upon activation,
preosteoclasts mature and become capable of bone resorption
(Negishi-Koga and Takayanagi, 2009). Therefore, osteoclast
function is a primary target in the therapy of osteoporosis, which
is reflected by the clinical use of potent bisphosphonate osteo-
clast inhibitors and, more recently, the cathepsin K inhibitors
(Stoch and Wagner, 2008). Noteworthy, CB2 receptor-selective
ligands have been shown to be significant modulators of osteo-
clast function with a potential to treat osteoporosis (Bab, 2007;
Idris and Ralston, 2010).
Opinions differ with regard to whether CB2 receptor agonists
or antagonists (inverse agonists) could be exploited to therapeu-
tically target bone degeneration (Lunn et al., 2008). While some
researchers concluded that CB2 receptor activation leads to
inhibition of bone formation (for review, see Bab et al., 2009),
other researchers argue in the opposite direction (Lunn et al.,
2007; Idris and Ralston, 2010). Thus, the data on effects of
different CB2 receptor-selective ligands on osteoclast develop-
ment and function are conflicting. Given the lack of insight into
the CB2 receptor-mediated effects in these cells, a better under-
standing of the CB2 receptor-mediated signal transduction in
osteoclastogenesis appears mandatory to shed light on their
role in bone formation.
In this study we report the discovery of an easily accessible
antiosteoclastogenic biphenyl scaffold derived from the neoli-
gnan 40-O-methylhonokiol (MH) naturally occurring in Magnolia
grandiflora L. seeds. MH binds to CB2 receptors with high affinity
and good selectivity over CB1 receptors and acts as a CB2
receptor inverse agonist. Some of the 44 MH derivatives ex-
hibited potent inverse agonist effects and showed a simulta-
neous [Ca2+]i stimulation, whereas few derivatives primarily
affected [Ca2+]i.
Although [Ca2+]i regulation is of paramount importance for
osteoclastogenesis and bone resorption (Negishi-Koga and
Takayanagi, 2009), the involvement of CB2 receptor-mediated
[Ca2+]i transients in osteoclastogenesis has not been elucidated
so far. An increase of [Ca2+]i would be expected to trigger oste-
oclast formation via activation of the transcription factor NF-ATc.
By using a novel type of CB2 receptor ligands we have assessed
the importance of the CB2 receptor-mediated cAMP and the
[Ca2+]i modulation for osteoclastogenesis.
RESULTS
Identification and Characterization of CB2 Receptor-
Selective Biphenyl Neolignans inMagnolia grandiflora
Seed Oil
In a screening initiative aimed at identifying new CB2 receptor-
selective ligands from plant extracts and purified secondary
metabolites (Gertsch et al., 2008, 2010), the seed oil ofMagnolia
grandiflora L., amedicinal plant native to the southeastern United
States and northern Mexico, scored as the most significant hit
out of more than 450 extracts. MH is only a minor secondary
metabolite in Asian Magnolia species but it is the major constit-
uent of M. grandiflora seeds. M. grandiflora seeds have been1054 Chemistry & Biology 18, 1053–1064, August 26, 2011 ª2011 Elused in traditional Mexican medicine to treat different ailments
such as spasms, infertility, epilepsy, and inflammatory diseases
(Martinez, 1959; Mellado et al., 1980). An overview of screening
data typically obtained in the radioligand displacement assays
using the high-affinity cannabinoid receptor ligand [3H]CP55,940
and membrane preparations from human CB2 receptor-trans-
fected HEK293 cells is shown in Figure 1A. The subsequent isola-
tion of the major secondary metabolites in the M. grandiflora
seedoil led to the identificationof the biphenyl neolignansmagno-
lol, honokiol, and40-O-methylhonokiol (MH)as active constituents
(structures shown in Figure 1B).
The binding affinities of the neolignans to CB receptors were
determined in radioligand displacement assays (Figure 1C) using
membranes from CB1 and CB2 receptor-transfected HEK293
cells. Hill plots and Ki values were generated as previously
described (Gertsch, 2008). While the stereoisomers magnolol
and honokiol showed moderate CB2 receptor binding affinity (Ki
values 1–3 mM), the natural honokiol derivative MH with
a methoxy group at 40 exhibited a remarkably strong binding
interaction with the human CB2 receptor (Ki = 43.9 ± 5.2 nM),
clearly accounting for most of the positive hit signal detected in
the initial screening. In the same assay, AEA, 2-AG and AM630
exhibitedKi valuesof 278±17, 892±51, and35.8±9nM, respec-
tively (Table 1). All three natural biphenyls showed a significantly
weaker binding affinity toward the human CB1 receptor (Fig-
ure 1C), the Ki value of MH being 2.4 ± 0.2 mM. Noteworthy, the
natural productMHshares structural similarities with someminor
constituents reported fromCannabis sativa L., i.e., cannabinodiol
and cannabinodivarin (Vollner et al., 1969), as well as with the
synthetic CB receptor ligands CP55,940 and HU308 (see Fig-
ure S1 available online). Since biphenyl containing compounds
are potentially privileged structures that may easily undergo
nonspecific interactions with proteins (Costantino and Barlocco,
2006), we next profiled magnolol, honokiol and MH in a receptor
screen comprising 50 pharmacologically relevant protein targets
(carried out at Novartis, Switzerland). The results of this screen
are summarized in Figure S2 and indicate a pronounced speci-
ficity of MH for the cannabinoid CB2 receptor.
MH Exerts CB2 Receptor-Dependent Mixed Inverse
Agonist and Agonist Effects
To assess the CB2 receptor-mediated functional effects of MH
(i.e., agonist, inverse agonist/antagonist, and silent antagonist),
cellular assays were carried out to measure forskolin-activated
and constitutive cAMP. In an assay using CHO-K1 cells stably
transfected with hCB2 receptors MH showed significant inverse
agonist effects, comparable to those evoked by the potent and
commercially available CB2 receptor-selective inverse agonists
AM630 and SR144528 (Figure 2A). To examine whether MH
was able to antagonize the Gi effects, i.e., the inhibition of
cAMP formation triggered by CB2 receptor agonists when stim-
ulated with 3 mM forskolin, the high-affinity ligand WIN55212-2
(hCB2 Ki 3 nM) was incubated alone (500 nM) and in the pres-
ence of increasing concentrations of the inverse agonists MH
and AM630. In these experiments, the antagonistic effect of
MH on the Gi protein-mediated inhibition of cAMP formation by
WIN55212-2 was in the range of that of AM630 (Figure 2B).
TheCB2 receptor-selective inverseagonistSR144528waspre-
viously shown to be an effective antagonist of 2-AG-stimulatedsevier Ltd All rights reserved
[3H]-CP55,940 binding to CB2 receptors (% of control)
M.grandiflora seed oil
A
B
C
Figure 1. Elucidation of Positive Hit in M. grandiflora Seed Oil (10 mg/ml) in Radioligand Displacement Assay Using hCB2 Receptor-Trans-
fected HEK293 Cell Membranes
(A) Shown is a representative test batch of 50 plant extracts. Several of the other positive hits with a displacement >50% (indicated with triangles) were due to the
widespread plant natural product b-caryophyllene as assessed by GC/MS dereplication experiments. The Magnolia seed oil contains three major neolignan
constituents visible in the HPLC chromatogram (on Agilent Zorbax RP-C18, 2.1 3 250 mm columb, flow 300 ml/min, gradient acetonitrile (10%–90%, 30 min) in
water, detection Agilent 1100 series diode array detector, temperature controlled at 25C).
(B) Structures of major secondary metabolites in M. grandiflora seed oil.
(C) Concentration-dependent displacement of [3H]CP55,940 in hCB2 (squares) and hCB1 (triangles) receptor-transfected HEK293 cell membranes by magnolol,
honokiol, and MH. The biphenyl MH is structurally related to cannabinoids (see also Figure S1) and specifically interacts with CB2 receptors (see Figures S2 and
S3) Determination of Ki values was based on the IC50 values from linearized data generated in Hill plots (not shown). Data are mean values ± SD (N = 4).
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Novel Biphenyl-Type CB2 Receptor Inverse Agonists[Ca2+]i in myeloid HL60 cells, whereas the inverse agonist AM630
in the same assay was ineffective (Sugiura et al., 2000), indicating
that different CB2 receptor inverse agonists exert distinct effects
on 2-AG-triggered [Ca2+]i. We tested MH together with
SR144528 and AM630 in an assay measuring inhibition of
2-AG-inducedCB2 receptor-stimulated [Ca
2+]i in an experimental
setup previously reported (Raduner et al., 2006). Rather unex-Chemistry & Biology 18, 1053–pectedly, instead of blocking the effects of 2-AG like SR144528
or being silent like AM630, MH potentiated the [Ca2+]i induced in
HL60 cells by 2-AG (Figure 2C). When incubated alone, MH
stimulated [Ca2+]i in HL60 cells in a concentration-dependent
manner (EC50 value 3 mM), with a potency comparable to that
of the endocannabinoid agonist 2-AG (Figure 2D) or b-caryophyl-
lene, a natural CB2 receptor-selective full agonist (Gertsch et al.,1064, August 26, 2011 ª2011 Elsevier Ltd All rights reserved 1055
Table 1. Summary of Binding Interactions with hCB1 and hCB2
Receptors
Cpd/Magreth No
CB2 Receptor Ki
Value (nM)
CB1 Receptor Ki
Value (nM)
AM630 35.8 ± 9 >3000
CP55,940 0.83 ± 0.09 0.49 ± 0.06
AEA 278 ± 17 ND
2-AG 892 ± 51 ND
MH 43.9 ± 5 2400 ± 200
1 74.0 ± 5 >2000
2 1305 ± 34 >5000
3a 40.8 ± 12 >5000
3b 59.1 ± 4 >5000
4 1763 ± 83 >5000
11a 1075 ± 14 >5000
11b 84 ± 14 860 ± 63
11c 427 ± 21 >5000
12a 1264 ± 60 >5000
12b 680 ± 49 >5000
14a 138 ± 7 790 ± 21
15 144 ± 5 >3000
16a 51 ± 1 1230 ± 30
16b 40 ± 3 970 ± 19
17a 57 ± 2 >5000
17b 46 ± 4 >5000
18a 102 ± 4 >5000
18b >3000 >5000
19 134 ± 12 >3000
Shown are the mean Ki values ± SD of at least three independent
measurements.
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Novel Biphenyl-Type CB2 Receptor Inverse Agonists2008). Thus, while acting as a CB2 receptor inverse agonist at the
level of cAMP, rather paradoxically, MH also showed agonist-like
effects at the level of [Ca2+]i in HL60 cells. Because the biphenyl
neolignan MH structurally resembles the GPR55 receptor
agonists Abn-CBD (abnormal cannabidiol) andO-1602,we inves-
tigated the possibility that MHmay trigger [Ca2+]i in HL60 cells via
the cannabinoid-like receptor GPR55 (Ross, 2009). In our assay,
the GPR55 receptor agonists Abn-CBD and O-1602 led to very
weak [Ca2+]i in HL60 cells which could not be blocked by
SR144528 (data not shown). This is in agreement with the obser-
vation that SR144528 and 2-AG do not functionally modulate
GPR55 receptor activity (Mackie and Stella, 2006). MH did not
interact with GPR55 receptors and did not lead to receptor
stimulation at low mM concentrations in hGPR55 transfected
HEKcells (see Figure S3). On the other hand, the [Ca2+]i transients
in HL60 cells triggered by MH could be blocked by SR144528
(Figure 2D), indicating that both compounds share the same or
overlapping binding sites despite of their functional differences.
The competitive binding to the CP55,940 binding site by MH
and SR144528 was substantiated by Dixon analyses (see Fig-
ure S4). We also measured [Ca2+]i in the stably CB2 receptor-
transfected CHO-K1 cell line in which we determined the inverse
agonist effects on cAMP (Figure 2F). Although the [Ca2+]i tran-
sients induced by MH were clearly smaller than in HL60 cells,1056 Chemistry & Biology 18, 1053–1064, August 26, 2011 ª2011 Elthey were reproducible and could be inhibited by SR144528.
Moreover, MH did not show an effect on [Ca2+]i in CB1 receptor-
transfected or untransfected control cells (Figure 2F). Based on
our finding that the natural product MH exerts an apparently
mixed (heteroactive) action at the CB2 receptor, leading to both
a potent inverse agonist effect at the level of cAMP and a signifi-
cant agonistic effect at the level of [Ca2+]i, we next explored the
underlying structure-activity relationships (SAR) of this biphenyl
scaffold in the context of their action on macrophage biology
and osteoclast formation.
Synthesis of Neolignan Derivatives and Measurements
of CB Receptor Binding Interactions
Given the easy accessibility of its structure, e.g., the lack of ster-
eocenters, a series of derivatizations on MH was carried out in
order to explore structural prerequisites for its activity. The re-
spective series of honokiol derivatives were obtained subse-
quently through demethylation. In addition, de novo syntheses
of biphenyls were carried out allowing the functionalization of
the aryl positions not easily accessible in naturally occurring neo-
lignans. As shown in Figure 3, the olefinic group of the side
chains, the phenolic hydroxyl group, and the aryl positions
were modified. The derivatizations based on MH comprised
hydrogenation, isomerization, hydroxylation, elongation, and
bromination of the side chains (Magreth-1 to -12b). The
acronymMagreth stands forMagnolia Graz and ETH. Derivati-
zation of the phenolic groups included acetylation and alkyl-
ations (Magreth-13a to -18c). Moreover, in ring A the introduc-
tion of an amino or nitro group was carried out leading to
derivatives Magreth-19a to -22. Table S2 shows methylated
magnolol derivatives (23-24b). In Table S3, biphenyls are shown
which were obtained by de novo syntheses (25-33) with the
exception of commercially obtained 25 and 26. The syntheses
were performed with the intention to obtain as many derivatives
as possible using straightforward methodologies. The resulting
library of 47 biphenyl-type compounds (see Tables S1–S3) was
then subjected to SAR relationship studies comprising cannabi-
noid receptor binding affinity and functional effects mediated via
the CB2 receptor. The synthetic steps leading to the most potent
CB2 receptor inverse agonists are provided in Figure 3.
The relative binding affinities toward cannabinoid receptors
CB1 and CB2 are shown in Table 1. Although different biphenyls
show significant differences in binding affinity toward the CB1
receptor, none of the compounds which displaced [H3]-
CP55,940 by more than 50% at 10 mM, yielded a Ki value signif-
icantly lower than 1 mM. This contrasts the overall good CB2
receptor binding affinity of various biphenyls which exhibited Ki
values in the lower nM range. In the following, the structure-
CB2 receptor binding relationships are summarized. Tetrahydro-
honokiol and tetrahydromagnolol showed a significantly re-
duced CB2 receptor binding affinity. Likewise, isomerization of
the side chain attached to ring B reduced the binding affinity.
Three derivatives here referred to as Magreth-31 to 33 based
on the symmetrical magnolol skeleton were synthesized in order
to elucidate the effect of different alkyl side chains.Magreth-31,
bearing methyl groups instead of allyl rests, completely lost CB2
receptor affinity.Magreth-32 and 33 with tert-butyl and isobutyl
groups, respectively, showed the same CB2 binding affinity as
the parent compound. Magreth-29, an isomer of magnololsevier Ltd All rights reserved
Figure 2. Characterization of Functional
Effects of MH
(A) Concentration-dependent inverse agonism
(potentiation of forskolin-activated [2 mM] cAMP
levels) in confluent hCB2 receptor-transfected
CHO-K1 cells by MH, SR144528, and AM630.
(B) MH inhibits the effect of WIN55,212-2 (500 nM)
on forskolin-stimulated cAMP in hCB2 receptor-
transfected CHO-K1 cells like AM630.
(C) MH potentiates the effect of 2-AG on intra-
cellular calcium ([Ca2+]i) in HL60 cells unlike
SR144528, which inhibits this effect, and AM630
which is silent.
(D and E) (D) Concentration-dependent effect of
MH on intracellular calcium in HL60 cells, 2-AG,
b-caryophyllene (E-BCP), and SR144528 were
used as controls, and (E) blockage of this effect at
10 mM MH by SR144528 (5 mM). Data are mean
values ± SD (N = 3).
(F) Effects of MH (2 mM) on [Ca2+]i in CB1 and CB2
receptor-transfected and untransfected CHO-K1
control cells. SR144528 (10 mM) inhibited the
[Ca2+]i triggered by MH, indicating an overlapping
binding site (see also Figure S4). Data were ob-
tained in FLIPR experiments and show mean
traces (N = 6). A representative experiment is
shown.
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inactive.
Hydrogenation of the side chain in MH did not significantly
change the binding affinity. Bromination of the side chain in
subsystem A greatly reduced affinity, whereas bromination in
system B did not change the binding affinity observed with
MH. As could be seen forMagreth-12a and 12b, the respective
honokiol side chain-brominated products showed an overall
greatly reduced binding affinity. Extension of side chains in
methylhonokiol by an n-butyl group led to a dramatic decrease
of binding affinity. Epoxidation or hydroxylation of both allyl
groups abolished CB2 receptor binding affinity. Simplified biaryls
such as the biphenylols Magreth-25 and 26 also possessed noChemistry & Biology 18, 1053–1064, August 26, 2011 ªbinding affinity. Depending on their
length, ether-linked alkyl rests at posi-
tions 2 and 40 had a different influence
on the CB2 receptor affinity. ForO-methyl
rests, compounds with ethers in both 2
and 40 positions showed high binding
affinity (Magreth-14a and MH); however,
the ether linkage with alkyl chains (C2–C5)
at position 2 showed a more notable
effect on binding affinity than alkyl chains
attached at 40. Alkyl chains > 2 carbons at
40 led to an abolishment of CB2 affinity
(e.g., in Magreth-17a/b versus Ma-
greth-16a/b). The di-O-alkylated com-
pounds in general showed a significant
loss of binding affinity (Magreth-14b,
16c, and 18c). This reduction of binding
activity is also observed in a derivative
containing hydrophobic groups such
as –OAc (Magreth-13a/b) or –OCH3
and –Si(CH3)2(t-Bu) inMagreth-9 at positions 2 and 4
0. The intro-
duction of a nitro group to position 3 in ring A of MH diminished
the CB2 binding affinity, whereas an amino function at the same
position increased binding affinity.
Characterization of the Effects of Magreth Ligands
on Gi and [Ca
2+]i Signals
The Magreth compounds listed in Table 1 were subjected to
functional assays measuring both cAMP in stably hCB2
receptor-transfected CHO-K1 cells and [Ca2+]i in CB2 receptor
expressing HL60 cells (see Figure S5). In particular, we were
interested to see whether the SAR correlated between the
inverse agonist (antagonist) and agonist effects originally2011 Elsevier Ltd All rights reserved 1057
Figure 3. Synthetic Steps Involved in the Generation of the Most Potent CB2 Receptor-Selective Inverse Agonists
See also Tables S1, S2, and S3.
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Novel Biphenyl-Type CB2 Receptor Inverse Agonistsobserved with the natural product MH (vide supra). A strong
positive correlation was found between the Ki values of the
compounds and their effects on [Ca2+]i, (r
2 = 0.82) but was less
pronounced with inverse agonism at the level cAMP (r2 =
0.59). While Magreth-16b, 17a, and 19 showed a more pro-
nounced [Ca2+]i (agonistic) effect, these compounds did not
show inverse agonism and therefore behaved like partial
agonists. In all cases, SR144528 blocked the [Ca2+]i (not shown),
thus indicating a CB2 receptor-mediated mechanism. Generally,
the biphenyls more easily activated CB2 receptor-mediated
[Ca2+]i than Gi effects. Magreth-3b was the only compound
that showed a more pronounced modulation of cAMP over
[Ca2+]i. Because Magreth-16a was more potent than MH as
CB2 receptor inverse agonist (cAMP) and agonist ([Ca
2+]i), (see
Figure S5), this compound was selected for further cellular
studies (vide infra).
Effects of Different Biphenyls on Monocyte/
Macrophage Chemotaxis and Osteoclastogenesis
Endocannabinoids have been shown previously to induce and/or
positively regulate chemotaxis in immune cells, includingmacro-
phages (Oka et al., 2004). Along the same line, CB2 receptor-
selective inverse agonists have been shown to inhibit chemo-
taxis (Lunn et al., 2006). CB2 receptor-selective inverse agonists
have also been shown to inhibit osteoclastogenesis and to
protect against bone loss (Lunn et al., 2007). We assessed the1058 Chemistry & Biology 18, 1053–1064, August 26, 2011 ª2011 Eleffects of the most potent Magreth ligands on 2-AG-induced
macrophage chemotaxis and MCSF/RANKL-stimulated osteo-
clast formation. We expected that more potent effects on either
cAMPor [Ca2+]i may lead tomore pronounced effects on chemo-
taxis and/or osteoclastogenesis. As shown in Figure 4, the more
potent inverse agonists, including the natural product MH, more
potently inhibited 2-AG-induced chemotaxis. Magreth-16a
(1 mM) andMHpotently inhibited both 2-AG-induced chemotaxis
and osteoclastogenesis (Figures 4 and 5). The antiosteoclasto-
genic effects of the Magreth compounds were observed at the
level of reduced TRAP staining and abolished RANK surface
expression in assays in which compounds were coincubated
with M-CSF/RANKL-stimulated monocytes/macrophages to
initiate osteoclastogenesis (Figure 5). During osteoclastogenesis
RANK expression was induced 8- to 15-fold as determined by
FACS immunofluorescence. Five hundred nanomolars of MH
andMagreth 1, 3a, 3b, 11b, 16a, and 16b significantly inhibited
osteoclast formation by 50% or more as determined by the inhi-
bition of syncytia formation (only shown for MH and 16b), the
number of tartrate-resistant acid phosphatase-positive
(TRAP+) cells, and RANK surface expression (Figure 5). While
in experiments using mouse preosteoclasts CB2 receptor
inverse agonist induced apoptosis (Idris et al., 2005), we did
not observe apoptotic preosteoclasts or macrophages in our
experiments with primary human cells or RAW264.7 cells (data
not shown). The potency of the effect on [Ca2+]i by theMagrethsevier Ltd All rights reserved
Figure 4. CB2 Receptor Inverse Agonists Inhibit 2-AG-Induced
Macrophage Chemotaxis
Bar graph showing the effect of pretreatment with different CB2 receptor
inverse agonists (10 min, 1 mM at 37C) on the capacity of primary monocytes/
macrophages to migrate toward 2-arachidonoyl glycerol (2-AG) (1 mM) (see
also functional effects in Figure S5). Bars below the IC50 line were all highly
significant. Data are expressed as mean arbitrary fluorescent units (AFU) +
SEM (N = 5).
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(r2 = 0.49).
Magreth-16a Inhibits the Osteoclastogenic Action
of Endocannabinoids
In our assay setup, the endocannabinoids 2-AG and AEA signif-
icantly potentiated macrophage colony stimulating factor
(MCSF) and RANKL-stimulated osteoclastogenesis in primary
monocytes/macrophages at 50–200 nM and thus more physio-
logically relevant concentrations (Figures 6A–6C). Upon endo-
cannabinoid treatment some osteoclast syncytia were larger
than the vehicle (DMSO) treated syncytia, some containing as
many as 30 nuclei (Figure 6C). We performed experiments in
which both the Magreth ligands and the commercial CB2
receptor-selective inverse agonists SR144528 and AM630
were incubated in the presence of nM concentrations of endo-
cannabinoids. SR144528 and AM630 inhibited the osteoclasto-
genic effect of AEA and 2-AG (data not shown). As shown in Fig-
ure 6B, the osteoclastogenic effect of a mixture of 50 nM of each
AEA and 2-AG (replaced every second day) (Figure 6C) was fully
inhibited by 200 nM ofMagreth-16a. Overall, this indicates that
the cAMPmodulation and not the [Ca2+]i mediates this action. In
our assay setup, the ligands clearly inhibited osteoclast forma-
tion beyond the number of osteoclasts formed by endocannabi-
noid stimulation. The same result was also obtained in RANKL-
stimulated RAW264.7 cells (data not shown). This suggested
that other osteoclastogenic factors different from endogenous
2-AG and AEA may be modulated via CB2 receptors. Based on
observations with SR144528 reported in an earlier study (Radu-
ner et al., 2006) we speculated that endogenous tumor necrosis
factor-a (TNF-a) production may be critically inhibited by the
novel CB2 receptor inverse agonists.
Magreth Derivatives Inhibit Endogenous and
LPS-stimulated TNF-a Expression in Monocytes/
Macrophages
TNF-a has previously been shown to stimulate osteoclastogen-
esis and inhibition of this osteoclastogenic cytokine is a widelyChemistry & Biology 18, 1053–reported mechanism to inhibit bone resorption (Boyle et al.,
2003). Somewhat paradoxically, CB2 receptor agonists (both
full and partial) as well as inverse agonists have been shown to
inhibit the expression of proinflammatory cytokines (i.e., TH1
cytokines) including TNF-a (for review, see Gertsch, 2008).
Therefore, the effect of CB2 receptor ligands on cytokine expres-
sion must involve signaling pathways independent of Gi/o, such
as e.g., [Ca2+]i or kinases. Therefore, we examined the effect
of the Magreth compounds on the expression of TNF-a in
LPS-stimulated primary human monocytes/macrophages and
RAW264.7 macrophages. Several of the Magreth compounds
(500 nM) potently inhibited TNF-a expression from stimulated
human monocytes/macrophages (see Figure S6), but they also
inhibited the constitutive TNF-a levels from RAW264.7 cells
(data not shown). Since the potency of CB2 receptor interaction
correlates with the degree of TNF-a inhibition measured (r2 =
0.67), a CB2 receptor-mediated mechanism seems likely, but
other mechanisms cannot be excluded. Importantly, the CB2
receptor-triggered [Ca2+]i does not seem to play a role in
TNF-a inhibition asMagreth-16b and 17a were only moderately
effective. Furthermore, in our experimental system SR144528
and AM630 both inhibited TNF-a expression, thus ruling out
the possibility of using these pharmacological inhibitors. Endo-
cannabinoids like anandamide also inhibit TNF-a expression
(Raduner et al., 2006) and may thus also have antiosteoclasto-
genic effects, depending on the actual concentration of TNF-a
in cell culture media. Five hundred nanomolars of 2-AG
inhibited TNF-a by approximately 30% in this assay (data not
shown).
DISCUSSION
The natural product 40-O-methylhonokiol (MH) was identified
from Magnolia grandiflora L. seed oil as a new CB2 receptor-
selective ligand. MH exhibits an intriguing nonspecific heteroac-
tive behavior at the CB2 receptor, i.e., acting as inverse agonist
at Gi/o and full agonist at [Ca
2+]i, thus providing a novel type of
functionally nonspecific CB2 receptor ligand. This suggests
that CB2 receptors respond to functionally diverse ligands by
displaying distinct conformational states with unique kinetic
profiles, rather than by acting as simple switches. Alternatively,
different subpopulations within the same assay couple to
different G proteins and our ligands are able to differentially
but simultaneously modulate these. This will have to be ad-
dressed in future studies. In the present study, the pharmaco-
phore of MHwas investigated by derivatization and the prepared
nanomolar CB2 receptor ligands were used to study effects on
osteoclastogenesis. Our results show that the endocannabi-
noids AEA and 2-AG exert osteoclastogenic effects at low nM
concentrations in human preosteoclasts by triggering syncytium
formation, and that CB2 receptor inverse agonists can block this
effect via inhibition of 2-AG-triggered chemotaxis. Although
2-AG exhibits a CB2 receptor Ki value in the low micromolar
range (Table 1) this endocannabinoid may activate the CB2
receptor at significantly lower concentrations without the need
of full receptor occupancy. The osteoclastogenic effect of endo-
cannabinoids has been reported previously (Idris et al., 2005)
and suggested to be CB receptor dependent, as indicated by
the fact that both CB1 and CB2 inverse agonists were able to1064, August 26, 2011 ª2011 Elsevier Ltd All rights reserved 1059
Figure 5. Biphenyl-Type CB2 Receptor
Ligands Inhibit Osteoclastogenesis in Pri-
mary Human CD14+ Monocytes/Macro-
phages and RAW264.7 Cells
(A) Effect of Magreth compounds (500 nM) on
osteoclastogenesis in MCSF (20 ng/ml)/RANKL
(50 ng/ml)-stimulated primary CD14+ human
monocytes/macrophages as determined by the
number of TRAP+ cells. For effects on TNF-a
expression see Figure S6. Data show mean
values + SD (N = 3) of osteoclasts/96 well at day
14. Medium was changed every second day.
(B) Dose-response curve of inhibitory action of
Magreth-16a, SR144528, honokiol, and MH in
RANKL (100 ng/ml)-stimulated RAW264.7 cells.
(C) Effect of Magreth-16a, SR144528, honokiol,
and MH on syncytium formation during osteo-
clastogenesis in RANKL (100 ng/ml)-stimulated
RAW264.7 cells. Data show mean values ± SD of
at least three independent experiments.
(D) Effect of Magreth compounds (500 nM) on
osteoclastogenesis in MCSF (20 ng/ml)/RANKL
(50 ng/ml)-stimulated primary CD14+ human
monocytes/macrophages as determined by
RANK surface expression.
Chemistry & Biology
Novel Biphenyl-Type CB2 Receptor Inverse Agonistsblock the action of AEA (for review, see Idris and Ralston, 2010).
In the case of AEA, the osteoclastogenic effect also involves the
TRPV1 channel (Rossi et al., 2009; Idris et al., 2010a) and
possibly GPR55 (Whyte et al., 2009). Our data obtained by
making use of the biphenyl scaffold substantiate that the clas-
sical CB2 receptor inverse agonists (antagonists) SR144528
and AM630 inhibit osteoclastogenesis independent of [Ca2+]i
modulation but are dependent on cAMP-mediated chemotaxis
of preosteoclasts and possibly inhibition of TNF-a expression.
Our data further indicate that even though in myeloid cells CB2
receptor-triggered [Ca2+]i may be physiologically relevant, this
does not seem to play a key role in osteoclast biology. This is
corroborated by the finding that both 2-AG and AEA similarly
stimulate osteoclastogenesis at low nanomolar concentrations,1060 Chemistry & Biology 18, 1053–1064, August 26, 2011 ª2011 Elsevier Ltd All rights resedespite the fact that only 2-AG triggers
[Ca2+]i in myeloid cells. We thus specu-
late that the CB2 receptor may switch its
functional signaling repertoire upon syn-
cytium formation. On the other hand, a
clear correlation was found between the
degree of inverse agonism, i.e., cAMP
modulation via the CB2 receptor and the
antiosteoclastogenic effects (r2 = 0.78).
TNF-a which is differentially expressed
by monocytes/macrophages, also af-
fects osteoclast formation and exerts
both osteoclastogenic and antiosteo-
clastogenic effects, depending on the
concentration and assay setup (Balga
et al., 2006). TNF-a inhibition is typically
also seen with CB2 receptor agonists
(Gertsch, 2008) and this may account
for differences in experimental results in
osteoclast assays, which may havebeen generated under different constitutive TNF-a levels and
distinct concentrations of CB2 receptor ligands tested.
Biphenyls are relatively rare in nature and it is quite remarkable
that MH is structurally albeit not biosynthetically related to the
cannabinodiol-type compounds from Cannabis sativa L. that
are derived from cannabinol. Cannabinodiol and cannabinodi-
varin are the only known Cannabis biphenyls (see Figure S1)
and are only found in trace amounts (Vollner et al., 1969; Turner
et al., 1980). To our knowledge, they have never been tested for
their action on CB receptors. A synthetic CB2 receptor-selective
agonist with certain structural similarity to MH is HU308, which
has been shown to inhibit osteoclastogenesis (Ofek et al.,
2006). In an in vitro screen of a panel of 50 receptors, MH only
showed ligand binding interactions with CB receptors (seerved
Figure 6. Magreth-16a Inhibits Osteoclastogenesis of MCSF (20 ng/ml)/RANKL (50 ng/ml)-Stimulated Primary Human CD14+ Monocytes/
Macrophages
Stimulation/treatment every second day over 14 days. Shown are TRAP+ stained cells (dark color), size bar is 100 mm, left 203 magnification, right
103magnification (A) Vehicle control, (B) Antiosteoclastogenic effect ofMagreth-16a (200 nM) in the presence of a combination of 50 nM of each 2-AG and AEA,
(C) Effect of a combination of 50 nM of each 2-AG and AEA. Data show mean values + SD (N = 3). Paired t test *, P<0.05.
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Figure S3). MH may therefore be highly selective toward CB2
receptors. Nevertheless, MH has previously been shown to
also inhibit COX-2 in vitro (Schu¨hly et al., 2009). Interestingly,
structurally related biphenylcarboxylic acid derivatives have
been described as a novel and therapeutically promising class
of bone resorption inhibitors (Van’t Hof et al., 2004; Idris et al.,
2010b) and could theoretically exert their antiresorptive effects
via CB2 receptor interactions. Honokiol, which binds to CB2
receptors at low mM affinity (Figure 1), has been shown previ-
ously to inhibit osteoclastogenesis in vitro at mM concentrations
(Ahn et al., 2006; Hasegawa et al., 2010), but in these studies no
reference was made to the ECS. The heteroactive (functionally
nonspecific) Magreth compounds reported here represent
a novel class of CB2 receptor ligands. They may be explored in
physiological systems and in disease contexts like bone loss.
SIGNIFICANCE
The CB2 receptor has attracted attention as a validated
target for the development of new therapeutic strategies
(Buckley, 2008) with an array of functionally different canna-
binoid receptor ligands already reported (Pertwee et al.,
2010). Our finding of a functionally novel class of a CB2Chemistry & Biology 18, 1053–receptor heterocative molecular template, which exerts
mixed inverse agonist responses together with a simulta-
neous CB2 receptor-mediated [Ca
2+]i either reflects the
pharmacophore complexity of the CB2 receptor or an
unexpected heterogeneity of CB2 receptor coupling within
the same cell line. The first would indicate that the current
concept of a bifunctional switch may be insufficient,
thus adding a new level of complexity to CB2 receptor
pharmacology.
The inhibition of 2-AG-triggered chemotaxis of pro-osteo-
clasts and inhibition of syncytium formation by CB2 receptor
inverse agonists (via cAMP)may help to further elucidate the
role of CB2 receptors in bone homeostasis. Osteoclasts are
cells of hematopoietic origin with a functional endocannabi-
noid system and the unique property of dissolving bone;
their inhibition is a hallmark for the treatment of diseases
of bone loss.
The biphenyl neolignan methylhonokiol, isolated from the
medicinal plant Magnolia grandiflora, is an easily acces-
sible and apparently nontoxic CB2 receptor ligand with
potential for the development of therapeutics for diseases
in which the CB2 receptor may play a role. These include
osteoarthritis, neuroinflammation, pain, and chronic bowel
disease.1064, August 26, 2011 ª2011 Elsevier Ltd All rights reserved 1061
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Materials
Sources are given in the Supplemental Information available online.
Data Analysis
Results are expressed as mean values ± SD or ± SEM for each examined
group. Statistical significance of differences between groups was determined
by the Student’s t test (paired t test) with GraphPad Prism5 software. Outliners
in a series of identical experiments were determined by Grubb’s test (ESD
method) with alpha set to 0.05. Statistical differences between treated and
vehicle control groups were determined by Student’s t test for dependent
samples. Differences between the analyzed samples were considered as
significant at p % 0.05. Nonlinear regression analysis (curve fitting) was per-
formed with GraphPad Prism5 software.
Screening of Plant Extract Libraries and Determination of Ki Values
and Receptor Screen
The radioligand assays used were described previously (Gertsch et al., 2008).
Data were fitted in a sigmoidal curve and graphically linearized by projecting
Hill plots, which for both cases allowed the calculation of IC50 values. Derived
from the dissociation constant (KD) of [
3H]CP-55,940 (0.39 nM) and the
concentration-dependent displacement (IC50 value), inhibition constants (Ki)
of competitor compounds were calculated by using the Cheng-Prusoff equa-
tion [Ki = IC50/(1 + L/KD)]. The procedure for the receptor screen is provided in
the Supplemental Experimental Procedures.
Cell Cultures
Human promyelocytic leukemia CB2-expressing (positive) HL60 cells (ob-
tained from the ATCC, CCL-240) were grown in Iscove’s modified Dulbecco’s
medium with 4 mm L-glutamine and 1.5 g/liter sodium bicarbonate (ATCC,
Manassas, VA) supplemented with 20% fetal bovine serum, 1 g/ml fungizone
(amphotericin B), 100 units/ml penicillin G, and 100 g/ml streptomycin. The
human CB2-expressing CHO-K1 cells were grown in the same medium as
the CB2-negative HL60 cells but supplemented with 400 mg/ml G418
(10131-027; Invitrogen). All cells were grown in a humidified incubator at
37C and 5% CO2. Isolation and culture of primary monocytes/macrophages
are described in the Supplemental Experimental Procedures.
Monocyte/Macrophage Chemotaxis In Vitro Assay
Primary humanmonocytes fromhealthy humandonorswere obtained as previ-
ously reported (Raduner et al., 2006). The monocytes were then differentiated
into macrophages in cultured in RPMI 640 medium supplemented with
10% (v/v) heat-inactivated fetal bovine serum, 100 U/ml penicillin G and
100 mg/ml streptomycin (Invitrogen, Switzerland) in a 5% CO2-humidified
incubator at 37C. Macrophage cell number was assessed by trypan blue
dye exclusion using a hematocytometer. Cells were then collected and
prepared as per manufacturer instructions for the QCM chemotaxis (8 mM)
cell migration assay (Millipore). In brief, 30,000 monocytes/macrophages
were seeded in the upper chamber of the provided 96-well plates. The lower
chambers were filled with conditioned medium with 2-AG (1 mM) or vehicle
control. The plates were then incubated overnight to allow for cell migration
through the pores and into the lower chamber or to the outside bottom of the
chamber. Anycells attached to theoutsideof thechamberweredetachedusing
the provided detachment buffer and collected according to manufacturer
instructions. Migrated cells were detached, lysed, and labeled with a fluores-
cent dye that exhibits strongfluorescencewhenbound to cellular nucleic acids.
Sample fluorescence was measured with a fluorescence microplate reader
(Farcyte Tecan, Switzerland). The excitation maximum was 480 nm; the
emission maximum was 520 nm.
Osteoclastogenesis Assays
The assays used to induce osteoclastogenesis in RAW264.7 macrophages
and primary human monocytes/macrophages are described in Supplemental
Experimental Procedures. The latter was adopted from Susa et al. (2004).
In brief, mononuclear cells were isolated from human peripheral blood by
density centrifugation, seeded at 600,000 cells per 96-well and cultured for
17 days in a-MEM medium, supplemented with 10% of selected fetal calf1062 Chemistry & Biology 18, 1053–1064, August 26, 2011 ª2011 Elserum, 1 mM dexamethasone and a mix of macrophage-colony stimulating
factor (M-CSF, 20 ng/ml), receptor activator of NFkB ligand (RANKL, 50 ng/ml),
and transforming growth factor-b1 (TGF-b1, 5 ng/ml).
Stimulation of TNF-a in Monocytes/Macrophages
Measurement of TNF-awas carried out as reported previously (Raduner et al.,
2006). A detailed procedure is provided in the Supplemental Information avail-
able online.
Measurements of [Ca2+]i Transients in HL60 cells and CHO-K1 cells
Measurements were carried out as reported previously (Raduner et al., 2006).
A detailed procedure is provided in the Supplemental Experimental
Procedures.
Characterization of Compounds
Characterization is provided in the Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, Supplemental Experimental
Procedures, and three tables and can be found with this article online at
doi:10.1016/j.chembiol.2011.05.012.
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